755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H).
Saved in:
| Title: | 755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H). |
|---|---|
| Authors: | Berton-Rigaud, D.1 (AUTHOR), Pautier, P.2 (AUTHOR), Lorusso, D.3 (AUTHOR), Gennigens, C.4 (AUTHOR), Gladieff, L.5 (AUTHOR), Kryzhanivska, A.6 (AUTHOR), Bowman, J.7 (AUTHOR), Tian, C.8 (AUTHOR), Cornfeld, M.7 (AUTHOR), Van Gorp, T.9 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS517-S517. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
